Pharmaceutical

Filter

Current filters:

None

Popular Filters

6651 to 6675 of 7138 results

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Germany’s IQWiG finds no added benefit for Novartis’ Rasilamlo

21-02-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether the drug…

Cardio-vascularEuropeNovartisPharmaceuticalRasilamloRegulation

Bayer to file for EU approval of aflibercept for central retinal vein occlusion

21-02-2012

German drug major Bayer (BAY: DE) says that it will file for European approval of its macular edema treatment…

afliberceptBayerEuropeEyleaOphthalmicsPharmaceuticalRegeneronRegulationResearch

EU approval for AstraZeneca thyroid cancer drug Caprelsa

21-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalRare diseasesRegulation

Finland’s reimbursement proposals short-sighted, says PIF

20-02-2012

Commenting on proposals by the Finnish government on reimbursement savings through cuts in drug wholesale…

EuropeHealthcarePharmaceuticalPricing

Clazosentan for traumatic brain injury shows promise in animals

20-02-2012

A new drug is showing promise in shielding against the harmful effects of traumatic brain injury (TBI)…

ActelionBiotechnologyclazosentanNeurologicalPharmaceuticalResearch

Flaws in ESI/Medco efficiency claims exposed

20-02-2012

David Balto, an antitrust attorney in Washington DC, USA, and former Policy Director of the Federal Trade…

Express ScriptsLegalMedcoMergers & AcquisitionsPharmaceutical

Opportunities for Pharma in narcolepsy

20-02-2012

The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

FDA approves first Cushing’s syndrome drug, Corcept’s Korlym

20-02-2012

Shares of USA-based Corcept Therapeutics (Nasdaq: CORT) leapt 62% to $4.90 in after-hours trading on…

Corcept TherapeuticsKorlymNorth AmericaNovartisPharmaceuticalRare diseasesRegulationSignifor

Vivo Ventures raises $375 million to invest in health care in USA and China

19-02-2012

Vivo Ventures, a health care investment firm with offices in Palo Alto, California, Shanghai, and Chengdu,…

Asia-PacificFinancialHealthcareNorth AmericaPharmaceutical

Four new drugs will change prostate cancer care, says US expert

19-02-2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer…

AlgetaAlpharadinAmgenBavarian NordicBayerJohnson & JohnsonOncologyPharmaceuticalProstvacXgevaZytiga

Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG

17-02-2012

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

EisaiEuropeHalavenOncologyPharmaceuticalPricingRegulation

UK NICE asks for more data on Tarceva, and Botox for migraine

17-02-2012

UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) today issued new draft…

AllerganBotoxEuropeNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarceva

Apricus collaborates with Sandoz for ED drug

17-02-2012

San Diego, USA-based Apricus Biosciences (Nasdaq: APRI) said yesterday that its wholly-owned subsidiary…

Apricus BioscienceEuropeLicensingMen's HealthNovartisPharmaceuticalReproductiveSandozVitaros

GlaxoSmithKline files for Tykerb/Tyverb with trastuzumab in USA and Europe

17-02-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday that it has submitted regulatory applications…

EuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrastuzumabTykerbTyverb

GSK and Novartis withdraw EU extended use applications for Tyverb and Fluad, respectively

16-02-2012

The European Medicines Agency has been formally notified by UK pharma giant GlaxoSmithKline (LSE: GSK)…

EuropeFluadGlaxoSmithKlineNovartisOncologyPharmaceuticalRegulationTyverbVaccines

Johnson & Johnson in deal with Australia University for spider venom pain research

16-02-2012

UniQuest, Australian University of Queensland’s (UQ) main research commercialization company, says…

Johnson & JohnsonNeurologicalPharmaceuticalResearch

AstraZeneca offering Arimidex for just $40 a month in USA

16-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has launched what it says is its first-ever direct-to-patient…

ArimidexAstraZenecaMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricing

Quintiles expands in MENA pharma markets

16-02-2012

Biopharmaceutical services company Quintiles is extending its global footprint to provide commercial…

Dayarn PharmaMarkets & MarketingPharmaceuticalQuintilesRegulationRest of the World

6651 to 6675 of 7138 results

Back to top